Results 131 to 140 of about 3,714 (189)

[Neuromuscular disorders due to adverse effects of antiparkinson agents].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Carotenoids as Antiparkinson Agents

2021
Parkinson’s disease (PD) is a neurodegenerative disease associated with the loss of dopaminergic neurons in the portions of the brain via multiple pathological mechanisms. Despite the fact that enormous progress occurred in the cure of Parkinson’s disorder, but the incidence and risk of this disease is increasing alarmingly over the past few decades ...
Saikat Dewanjee, Muhammad Zia-Ul-Haq, Muhammad Riaz, Shounak Sarkhel, Pratik Chakraborty, Sagheer Ahmed   +5 more
openaire   +1 more source

POTENTIAL FOR ABUSE OF ANTIPARKINSON AGENTS

Psychiatric Services, 1982
Hospital &‘ Community Psychiatrj is expanding its roster of peer reviewers for manuscripts submitted for publication. Professionals in the mental health disciplines who are qualified to serve as peer reviewers are invited to contact the editor. Reviewers must have significant publications in their specialty area, be abreast of the liteEature in that ...
James M. Smith, Winston W. Shen
openaire   +2 more sources

Quantitative Determination of Some Synthetic Antiparkinsonism Agents

Journal of Pharmaceutical Sciences, 1968
Nonaqueous titrimetry was employed to estimate quantitatively some of the compounds which are useful in treating Parkinsonism. The method was applied to both the crystalline material and their dosage forms. This technique was found to yield results which agreed well with those obtained by either the official procedures or by methods submitted by the ...
L G, Chatten, W J, Racz
openaire   +2 more sources

New L‐Dopa Codrugs as Potential Antiparkinson Agents

Archiv der Pharmazie, 2008
AbstractThis paper reports the synthesis and preliminary evaluation of newL‐dopa (LD) conjugates (1and2) obtained by joining LD with two different natural antioxidants, caffeic acid and carnosine, respectively. The antioxidant efficacy of compounds1and2was assessed by evaluating plasmatic activities of superoxide dismutase (SOD) and glutathione ...
SOZIO, Piera, IANNITELLI, ANTONIO, CERASA LS, CACCIATORE, Ivana, CORNACCHIA, CATIA, GIORGIONI G, RICCIUTELLI M, NASUTI C, CANTALAMESSA F, DI STEFANO, Antonio   +9 more
openaire   +4 more sources

Reactions to Antiparkinson Agents

1987
The cardiovascular effects are dose-related. Low doses can cause transient bradycardia; moderate or high doses can cause tachycardia, palpitation, and arrhythmias (due to blockage of vagal effects on the S-A node).
Frank L. Tornatore, John J. Sramek, Bette L. Okeya, Edmond H. Pi   +3 more
openaire   +1 more source

Some New Piperazino Derivatives as Antiparkinson and Anticonvulsant Agents

Archiv der Pharmazie, 1983
AbstractThe piperazino derivatives 1–7 were synthesized and evaluated for their antiparkinson activity on oxotremorine‐induced tremors and reserpine‐induced rigidity. The same compounds were screened for their anticonvulsant activity. Compounds 1, 3, 4 and 5 showed promising antiparkinson activity.
J C, Agarwal, C, Nath, M, Sharma, G P, Gupta, K P, Bhargava, K, Shanker   +5 more
openaire   +2 more sources

[Immunotropic activity of a potential antiparkinson agent himantane].

Eksperimental'naia i klinicheskaia farmakologiia, 2001
N-(Adamant-2-yl) hexamethyleneimine hydrochloride (A-7, himantane), a new potential antiparkinsonian drug belonging to the class of aminoadamantyl derivatives, exhibits pronounced immunomodulant activity in a therapeutic dose of 10 mg/kg. A single intraperitoneal injection of himantane stimulated a high B-lymphocyte activity in mice over a period of 21
G I, Nezhinskaia, E A, Val'dman, P G, Nazarov, T A, Voronina   +3 more
openaire   +2 more sources

Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms

American Journal of Health-System Pharmacy, 1979
The types of extrapyramidal syndrome (EPS) reactions produced by antipsychotic agents and the prophylactic use of antiparkinson agents in preventing EPS are reviewed. EPS are classified as akathisias, dystonias, parkinson-like symptoms and tardive dyskinesia, and have a varied incidence reported to range from 10.6 to 100%.
J E, Murphy, R B, Stewart
openaire   +2 more sources

Metabolism of antiparkinson agent dopazinol by rat liver microsomes.

Drug Metabolism and Disposition, 1990
Metabolism of dopazinol (DZ) by liver microsomes from control and phenobarbital- and 3-methylcholanthrene-treated rats has been investigated. Liver microsomes from control and treated rats metabolized DZ to N-despropyl-DZ (39-53% of total metabolites); 8-hydroxy-DZ, a catechol metabolite (32-39%); and 5- or 6-hydroxy-DZ (12-20%).
K P, Vyas, P H, Kari, H G, Ramjit, S M, Pitzenberger, M, Hichens   +4 more
openaire   +2 more sources